(NASDAQ: HALO) Halozyme Therapeutics's forecast annual revenue growth rate of 19.49% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.07%.
Halozyme Therapeutics's revenue in 2025 is $1,015,324,000.On average, 5 Wall Street analysts forecast HALO's revenue for 2025 to be $147,172,761,120, with the lowest HALO revenue forecast at $145,899,359,100, and the highest HALO revenue forecast at $148,374,734,400. On average, 5 Wall Street analysts forecast HALO's revenue for 2026 to be $182,092,055,352, with the lowest HALO revenue forecast at $176,207,312,400, and the highest HALO revenue forecast at $188,214,729,900.
In 2027, HALO is forecast to generate $212,390,279,565 in revenue, with the lowest revenue forecast at $202,712,301,060 and the highest revenue forecast at $222,278,849,700.